<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
AUGUST 14, 2000
ARQULE, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 000-21429 04-3221586
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
19 PRESIDENTIAL WAY, WOBURN, MASSACHUSETTS 01801
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code:
(781) 994-0300
<PAGE> 2
ITEM 5. OTHER EVENTS.
On August 14, 2000, ArQule, Inc. entered into an Amendment No. 1 to a
Compound Supply and License Agreement. This Current Report on Form 8-K is filed
solely to file such agreement.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(a) FINANCIAL STATEMENTS OF BUSINESS ACQUIRED.
Not applicable.
(b) PRO FORMA FINANCIAL INFORMATION.
Not applicable.
(c) EXHIBITS.
99.1* Amendment No. 1 to Compound Supply and License Agreement,
dated August 14, 2000, by and between ArQule, Inc. and R.W.
Johnson Pharmaceutical Research Institute.
* This Exhibit has been filed separately with the Commission pursuant to an
application for confidential treatment. The confidential portions of this
Exhibit have been omitted and are marked by an asterisk.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: October 17, 2000 ARQULE , INC.
By: /s/ Stephen A. Hill
-------------------------------------
Stephen A. Hill
President and Chief Executive Officer
<PAGE> 4
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT
NO. DESCRIPTION
------- -----------
<S> <C>
99.1* Amendment No. 1 to Compound Supply and License Agreement,
dated August 14, 2000, by and between ArQule, Inc. and R.W.
Johnson Pharmaceutical Research Institute.
</TABLE>
----------------------------
* This Exhibit has been filed separately with the Commission pursuant to an
application for confidential treatment. The confidential portions of this
Exhibit have been omitted and are marked by an asterisk.
